Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taf12 shRNA is a short hairpin RNA designed to silence the expression of TATA-box binding protein associated factor 12 (Taf12), a subunit of the TFIID co-activator complex. Research conducted at Cold Spring Harbor Laboratory demonstrated that Taf12 is essential for the maintenance of acute myeloid leukemia (AML) cells. Mechanistically, Taf12 inhibition selectively suppresses the transcription of core targets of the oncogenic transcription factor Myb. This effect is mediated through the physical interaction between the histone fold domain (HFD) dimer of Taf12/Taf4a and the transactivation domain of Myb. In preclinical models, Taf12 shRNA showed potent anti-leukemic activity in vitro and in vivo without affecting normal myeloid cells, suggesting a therapeutic window for AML treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on taf12 shRNA.